tbuckley/cabot-search huggingface dataset:
Hyperactive Transposase Mutants of the Sleeping Beauty Transposon
Authors: James Baus, Li Liu, Arnold D. Heggestad, Sonia Sanz, Bradley S. Fletcher
Journal: Molecular Therapy (2005)

Transposable elements have enormous potential to overcome one of the major hurdles in nonviral gene delivery, namely the lack of long-term gene expression. The Sleeping Beauty (SB) transposon is a promising vector system for nonviral gene therapy as it has the highest transposition activity of all known DNA transposons within mammalian cells. In an effort to generate a more efficient delivery vehicle, we conducted a systematic evaluation of several novel and previously identified SB transposase mutants. The results indicate that certain combinations of mutants do not enhance transposition, whereas others give a synergistic response. The most active mutant, designated HSB17, shows nearly 17-fold higher transposition activity compared to the original transposase SB10 when tested within the same expression cassette. In addition, synergistic activity is observed when this hyperactive mutant is combined with an improved transposon. Animal studies utilizing the hyperactive transposase show enhanced long-term reporter gene expression. These modifications further expand the utility of this transposon-based gene transfer system.
The Chronicity of Chronic Disease
Authors: Theresa Cullen
Journal: JAMA (2004)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Mycophenolate‐based graft versus host disease prophylaxis is not inferior to methotrexate in myeloablative‐related donor stem cell transplantation
Authors: Nada Hamad, Mohamed Shanavas, Fotios V. Michelis, Jieun Uhm, Vikas Gupta, Matthew Seftel, John Kuruvilla, Jeffrey H. Lipton, Hans A. Messner, Dennis (Dong Hwan) Kim
Journal: American Journal of Hematology (2015)

We retrospectively reviewed 242 patients who received related donor myeloablative peripheral blood hematopoietic cell transplantation. We compared patients who received mycophenolate (MMF)/cyclosporine (CSA) (n = 71), to historical controls who received methotrexate (MTX)/CSA (n = 172). There were no differences in overall survival, nonrelapse mortality, and relapse. The MMF/CSA group had significantly faster neutrophil and platelet engraftment: medians of 13 versus 18 days and 10 versus 14 days, respectively (P = 0.001). The cumulative incidence of acute graft versus host disease (GVHD) (Grades, 2-4) was significantly lower in the MMF/CSA group (45.1 vs. 74.4%, P < 0.001). The MMF/CSA group showed a lower incidence of skin (51.5 vs. 72.1%, P < 0.001) and liver acute GVHD (11.3 vs. 54.2%, P < 0.001) and a higher incidence of lung (42.2 vs. 19.0%, P = 0.045), eye (59.7 vs. 30.1%, P < 0.001), and mouth (72.8 vs. 56.4%, P = 0.001) chronic GVHD but only eye chronic GVHD was confirmed in propensity score matching (PSM) analysis. The incidence of cytomegalovirus (CMV) viremia was higher in the MMF/CSA group (55.8 vs. 39.6%, P < 0.001) but this was not confirmed in PSM analysis. MMF/CSA was identified as an independent favorable factor for acute GVHD (P < 0.001, hazard ratio, 0.41) but as a possible adverse risk factor for CMV viremia as this was not found to be statistically significant in PSM analysis. MMF/CSA in myeloablative matched related donor peripheral blood stem cell transplant is not inferior as GVHD prophylaxis in comparison with MTX/CSA and is associated with faster engraftment but a potentially higher risk of CMV viremia.
Stroke: A Clinical Approach.
Authors: Louis R. Caplan, Robert W. Stein
Journal: Annals of Internal Medicine (1987)

Part 1 General principles: introduction and perspective basic pathology, anatomy and pathophysiology of stroke diagnosis and the clinical encounter laboratory diagnosis treatment. Part 2 Stroke syndromes: large vessel occlusive disease of the anterior circulation large vessel occlusive disease of the posterior circulation penetrating and branch artery disease non-atherosclerotic ischemia brain embolism hypoxic-ischemic encephalopathy sub-arachnoid haemorrhage intra-cerebral haemorrhage strokes in children and young adults spinal cord strokes strokes, cerebrovascular disease and surgery. Part 3 Prevention, complications and rehabilitation: stroke prevention and risk factors complications in stroke patients rehabilitation.
NIH Panel Tries to Clear Confusion, Spur Research on Managing Menopause
Authors: Rebecca Voelker
Journal: JAMA (2005)

get both children and adolescents. Comic strip figure Garfield serves as “spokescat” for the “Star Sleeper” program of the National Center on Sleep Disorders Research (http://www.nhlbi .nih.gov/health/public/sleep/starslp/). The National Sleep Foundation offers “Time to Sleep With P.J. Bear” (http: //www.sleepforkids.org/html/pjbear .html). The National Institutes of Health offers a 5-unit curriculum supplement for grades 9-12 titled Sleep, Sleep Disorders , and Biological Rhythms (http://osedev.od.nih.gov /supplements/nih3/sleep/default .htm). A Detroit program distributes sleep kits containing a sleeping bag, pillow, activity book, toothbrush, and other bedtime items to city children (http://sweetdreamzzzdetroit.org/). In Connecticut, sleep specialists have teamed up with local medical societies and the League of Women Voters to raise awareness of adolescent sleep needs.
Analysis of TDP-43 and its binding partners in neurodegenerative diseases
Authors: Wejdan Kattuah, Claire Troakes, Tibor Hortobagyi, Boris Rogelj, Christopher Shaw
Journal: Molecular Neurodegeneration (2013)

Background Transactive DNA binding protein (TDP-43) is the major component of the ubiquitin-positive protein aggregates seen in ~90% of Amyotrophic Lateral Sclerosis (ALS) and 60% of Frontotemporal Lobar Degeneration (FTLD) cases [1]. We have previously shown that mutations in the gene encoding TDP-43 are causally linked to familial ALS+/-FTLD [2] TDP-43 belongs to the heterogeneous nuclear ribonucleoprotein (hnRNP) family of proteins that are involved in the regulation of RNA transcription, splicing, transport and translation [3]. There are a large number of hnRNPs, many of which have overlapping functions and often act cooperatively in RNA processing. Here we sought to determine whether TDP-43 aggregates contain other hnRNPs that might contribute to the neurodegenerative process.
Abstract 830: Disulfiram is a potent inhibitor of topoisomerase II
Authors: Xing Wu, Jack C. Yalowich, Daywin Patel, Brian B. Hasinoff
Journal: Cancer Research (2014)

Abstract Disulfiram is used in the treatment of alcoholism. It has also shown promise as an anticancer drug. The disulfide bond in disulfiram is metabolized in vivo to diethyldithiocarbamate (DDTC) which forms an extremely strong complex with copper(II) through which it may exert its cytotoxicity. Both disulfiram and diethyldithiocarbamate inhibited K562 cell growth in the low nanomolar range. The addition of the copper(II) chelators Trien and ammonium tetrathiomolybdate to the cell culture medium significantly reduced the cytotoxicity of disulfiram and diethyldithiocarbamate towards K562 cells, which suggests that their cytotoxicity is mediated by uptake of trace amounts of copper from the culture medium. Disulfiram, but not DDTC, strongly inhibited the decatenation activity of topoisomerase IIα in the low micromolar concentration range. Disulfiram, but not DDTC, also was shown to be a topoisomerase IIα poison as evidenced by its ability to induce formation of linear DNA. However, the K/VP.5 cell line, a K562-derived etoposide-resistant cell line with reduced levels of topoisomerase II, was not cross-resistant to either disulfiram or DDTC. K562 cells depleted in GSH levels by treatment with buthionine sulfoximine did not show increased sensitivity to disulfiram or DDTC. Disulfiram and DDTC also did not increase dichlorofluorescein fluorescence in K562 cells. These latter two results suggest that copper-mediated oxidative stress may not be a significant factor in their cytotoxicity. In summary, these results showed that while disulfiram and DDTC inhibited topoisomerase IIα, this inhibition may be only partly responsible for their cytotoxicity. Support: CIHR, a Canada Research Chair in Drug Development to B.B.H., and a National Institutes of Health grant CA090787 to J.C.Y. Citation Format: Xing Wu, Jack C. Yalowich, Daywin Patel, Brian B. Hasinoff. Disulfiram is a potent inhibitor of topoisomerase II. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 830. doi:10.1158/1538-7445.AM2014-830
A BCR-ABLp190 Fusion Gene Made by Homologous Recombination Causes B-Cell Acute Lymphoblastic Leukemias in Chimeric Mice With Independence of the Endogenous bcr Product
Authors: A. Castellanos, B. Pintado, E. Weruaga, R. Arévalo, A. López, A. Orfao, I. Sánchez-Garcı́a
Journal: Blood (1997)
Comparison of Diets for Weight Loss and Heart Disease Risk Reduction
Authors: John H Kelly
Journal: JAMA (2005)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Migraine as a Risk Factor for Subclinical Brain Lesions
Authors: Osama O. Zaidat
Journal: JAMA (2004)

To The Editor: Dr Kruit and colleagues 1 concluded that some patients with migraine, either with or without aura, are at increased risk for subclinical brain lesions. I have several reservations about the design and analysis of this study. First, the study was underpowered due to insufficient outcomes, which limits the number of potential confounding factors that can be included in the analysis. Second, and related to this lack of statistical power, the authorsbasedtheirconclusionontheirsecondaryoutcomeofincreased brain lesion load in the posterior circulation. The primary outcome in the study—increased total brain lesion load in any location—was not statistically different between the patients with migraine headache and those without. The sample size and the power calculation were based on the primary outcome; thus, any secondary outcome results would also be underpowered and would require an additional power calculation.
Abstract 17968: Increased Risk of Post-Heart Transplant Mortality in Small Infants
Authors: Heang M Lim, Justin Godown, Sunkyung Yu, Janet E Donohue, Joshua M Friedland-Little, Robert J Gajarski, Kurt R Schumacher
Journal: Circulation (2014)

Background: Infants awaiting heart transplant (HTx) continue to have high waitlist and early post-HTx mortality. The impact of small patient size on wait-list and post-HTx outcomes in infants has not been well studied. The objective of this study was to assess the effect of small size at the time of listing on waitlist outcomes, post-HTx mortality, and post-HTx complications. Methods: Infants weighing < 5kg listed for HTx from 1994-2013 were identified from the Organ Procurement and Transplantation Network database. The cohort was divided into 2 groups: < 3kg and 3-5kg. Waitlist duration was compared using Wilcoxon rank sum test. Waitlist mortality was examined using competing risk analysis, with delisting as a competing risk. Cox proportional hazard model assessed the impact of size at listing on post-HTx 1-year mortality. Results: Of 1,966 infants included in the analysis, 442 (22.5 %) weighed < 3 kg, and 1,524 (77.5 %) weighed 3-5 kg at listing. Between the two groups, there was no significant differen...
Commentary: eczema and cancer risk
Authors: J. Schmitt
Journal: British Journal of Dermatology (2011)

Journal Article Commentary: eczema and cancer risk Get access J. Schmitt J. Schmitt Institute of Occupational and Social Medicine,Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden, Fetscherstraße 74, 01307 Dresden, Germany E‐mail: jochen.schmitt@uniklinikum‐dresden.de Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 165, Issue 3, 1 September 2011, Pages 463–464, https://doi.org/10.1111/j.1365-2133.2011.10543.x Published: 01 September 2011
Epileptic Seizures. Clinical and Electrographic Features, Diagnosis and Treatment.
Authors: Henri Gastaut, Roger J. Broughton
Journal: Annals of Internal Medicine (1973)

Physicians examining newborn infants should no longer dread the discovery of unusual skin problems. Practical dermatologic help is now available in this highly readable text, the first in English dealing exclusively with neonatal skin. It particularly encourages pediatricians to carefully examine the skin of newborns for signs of prematurity, infection, inherited disease, and birth trauma. Detection of premature skin with its poor vasomotor tone, inability to sweat, and reduced fat pad insulation signals danger of thermal instability and the need for controlled environmental temperature. Increased percutaneous absorption in such skin adds additional risk from bathing with toxic substances such as hexachlorophene or boric acid. Increased desquamation occurs with prolonged gestation of 40 to 42 weeks and with dysmaturity from prenatal anoxia. Dysmature skin also demonstrates meconium staining and long hair and nails. Nursery personnel should readily recognize the common, transient, benign skin lesions described in this book, as concerned mothers will appreciate intelligible explanations for milia, miliaria, salmon patches, mongolian spots, erythema toxicum neonatorum, cutis marmorata, and neonatal acne. Detailed information is also given for many severe skin dis¬ eases, which are organized by chap¬ ters into morphologically similar groups such as vesiculobullous erup¬ tions, scaling disorders, and vascular malformations. Special attention is given to pigmentary disorders indica¬ tive of genetic diseases like neurofibromatosis and tuberous sclerosis. The dermatologie novice will bene¬ fit greatly from chapters on basic ter¬ minology, diagnostic technique, and topical therapy. Also helpful are the plentiful references, current to 1972, and numerous tables which consoli¬ date key facts, such as causes of pur¬ pura, signs of congenital syphilis, and types of ichthyosis. Photographs are abundant, with 62 in color, but are of
Abstract 20049: Double versus Provisional Stent Strategy for Coronary Bifurcation Using Drug-Eluting Stents: A Meta-Analysis of Randomized Controlled Trials
Authors: Alok Saurav, Ajay K Kaja, Manu Kaushik, Michael DelCore, Aryan V Mooss, William Biddle
Journal: Circulation (2014)

Introduction:  Percutaneous coronary intervention (PCI) of coronary artery bifurcation (CAB) has been performed with double stent (DS) strategy or strategy of provision stenting (PS) of side branch. However, the superiority of one strategy over other is not established especially in the era of newer generation drug eluting stenting (DES). To compare the clinical and angiographic outcomes of DS versus PS strategies for CAB lesions, we performed a systematic review and meta-analysis of randomized trials using DES.   Methods:  PubMed, Cochrane and Web of Science databases were searched through June 15th 2014 for RCTs comparing DS versus PS strategy for CAB using DES. Both clinical [cardiac mortality, myocardial infarction (MI), definite stent thrombosis (ST), TVR] & angiographic outcomes (binary restenosis rate of >50%, in-stent late loss) were assessed. Study quality, publication bias, heterogeneity were assessed. Random effect model used for data analysis.   Results:  Ten RCTs comprising 2585 patients (DS group=1318 PS group=1267) were selected for analysis. Gender (males: DS 78%, PS 77%) & age (DS 63.5, PS 64.3 years) distribution were similar in both groups. Follow up period varied from 6 months to 1 year for all studies. There was no significant difference in overall cardiac mortality (RR 0.87 CI 0.29-2.62, p=0.8) and definite ST (RR: 1.67 CI 0.69-4.07, p=0.25) rates between DS & PS groups. There was a trend towards higher sub-acute ( 50% remained comparable between two groups (MB: p = 0.32, SB: p=0.39).   Conclusion:  DS strategy significantly reduces TVR & SB related late loss compared to PS during PCI of CAB using DES. DS is also superior in terms of lower MI rates while cardiac mortality & definite ST are comparable to PS strategy.
Barriers to Children Walking to or From School—United States, 2004
Authors: S Martin, S Carlson
Journal: JAMA (2005)

infections include (1) asking known contacts whether they have heard from patients since the hurricane, (2) visiting locations known to be frequented by patients before the hurricane, (3) calling all known phone numbers for each patient, (4) checking public registries (e.g., American Red Cross Family Linking at http://www .katrinasafe.org)for updated news on patient whereabouts, and (5) seeking access to mortality records and other registries for cross-matching.A Katrina Help Desk was established on September 2 at the CDC Division of Tuberculosis Elimination to facilitate communication between the National TB Controllers Association and state TB programs as patients were relocated to other states.Health-care providers should immediately contact their state TB controllers (available at http://www.cdc.gov/nchstp/tb/katrina/tbcontrollers.htm) if an evacuee has TB symptoms (i.e., cough of Ն3 weeks duration, fever, chills, night sweats, or recent weight loss) or was under treatment for TB disease.The Louisiana TB Control Program (telephone 337-262-5616) will provide information about treatment regimens previously administered to relocated patients.If providers are unable to reach a local or state TB controller, they may contact the CDC Division of Tuberculosis Elimination at telephone 404-639-8336 for assistance.
Abstract 2821: Dual-label microdosing approach to identify chemoresistance to carboplatin and gemcitabine combination chemotherapy
Authors: Maike Zimmermann, Tiffany M. Scharadin, Hongyong Zhang, Tzu-yin Lin, Ralph W. deVere White, Chong-xian Pan, Paul T. Henderson
Journal: Cancer Research (2014)

Abstract Gemcitabine is commonly given in combination with cisplatin or carboplatin (GC therapy) as the first-line chemotherapy regimen for several malignancies, including bladder cancer. Unfortunately, less than half of patients respond to the therapy, generating a critical need for a test that predicts tumor response to GC therapy. The goal of this project is to measure drug-DNA adducts after administration of a single non-toxic microdose of gemcitabine in combination with carboplatin and correlating the degree of modification to chemotherapy sensitivity. We have previously shown that resistance to carboplatin may be identified by using a [14C]carboplatin microdose (1% of therapeutic dose), and subsequent measurement of the [14C]-DNA adducts via accelerator mass spectrometry (AMS), an ultrasensitive method used for detecting rare isotopes. We postulate that adduct levels induced in tumors by GC microdoses are proportional to those formed during full dose chemotherapy. Furthermore, we hypothesize that there exists a threshold level of adducts above which tumors respond to GC therapy. We used bladder cancer cell lines and the nod scid gamma severe combined immunodeficient (NSG) mice containing patient-derived tumor xenografts (PDX) from bladder cancer patients to determine GC-DNA adduct levels using AMS. The NSG mouse is uniquely capable of accepting and propagating tumor tissue engrafted directly from patient biopsy samples. The resulting groups of mice each have identical tumors, but can be treated in a variety of ways with replicate experiments; characteristics that are impossible to achieve in normal clinical studies. We will report progress on developing protocols and preliminary GC microdosing data using the NSG-PDX mouse model of human bladder cancer. Citation Format: Maike Zimmermann, Tiffany M. Scharadin, Hongyong Zhang, Tzu-yin Lin, Ralph W. deVere White, Chong-xian Pan, Paul T. Henderson. Dual-label microdosing approach to identify chemoresistance to carboplatin and gemcitabine combination chemotherapy. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 2821. doi:10.1158/1538-7445.AM2014-2821